// App-Quantinova.ai

325 : Evaluating the consequences of MCT1 inhibition in Burkitt lymphoma following treatment with AZD3965

Researchers

Presenter

  • Richard A. Noble

Principal Investigators

  • Natalie Bell

  • Helen Blair

  • Huw D. Thomas

  • Simon Bomken

  • Susan E. Critchlow

  • Stephen R. Wedge

Medical Centers

  • Northern Institute for Cancer Research Newcastle University, Newcastle, United Kingdom

  • Oncology Innovative Medicines Unit, AstraZeneca, Cambridge, United Kingdom.

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

  • Burkitt lymphoma

  • Non‐Hodgkin Lymphoma

  • Lymphomas

  • Solid malignancies

Biomarkers

  • cMYC

  • Lactate

Drug/Treatment

  • AZD-3965

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved